These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39479810)

  • 21. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
    Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S
    Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.
    Shiba N; Funato M; Ohki K; Park MJ; Mizushima Y; Adachi S; Kobayashi M; Kinoshita A; Sotomatsu M; Arakawa H; Tawa A; Horibe K; Tsukimoto I; Hayashi Y
    Br J Haematol; 2014 Jan; 164(1):142-5. PubMed ID: 24033149
    [No Abstract]   [Full Text] [Related]  

  • 24. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia.
    Wang T; Hua H; Wang Z; Wang B; Cao L; Qin W; Wu P; Cai X; Chao H; Lu X
    Hematology; 2022 Dec; 27(1):994-1002. PubMed ID: 36066283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF
    Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
    Ahmad F; Rajput S; Mandava S; Das BR
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
    He J; Liu J; Shen H; Wang Z; Cao L; Wu P; Chao H; Lu X; Jia Z; Chen M; Cai X
    Int J Hematol; 2022 Jul; 116(1):71-80. PubMed ID: 35314954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
    Marceau-Renaut A; Guihard S; Castaigne S; Dombret H; Preudhomme C; Cheok M
    Am J Hematol; 2015 May; 90(5):E93-4. PubMed ID: 25611491
    [No Abstract]   [Full Text] [Related]  

  • 29. [CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA].
    Zhu MY; Zhu Y; Chen RR; Zhu LX; Zhu JJ; Li XY; Zhou D; Yang XD; Zheng YL; Xie MX; Sun JN; Huang XB; Li L; Xie WZ; Ye XJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):100-105. PubMed ID: 32135624
    [No Abstract]   [Full Text] [Related]  

  • 30. [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].
    Zhang JP; Lin D; Wang SC; Li Y; Chen YM; Wang Y; Wei H; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1008-1012. PubMed ID: 33445848
    [No Abstract]   [Full Text] [Related]  

  • 31. Mutations in the bZip region of the CEBPA gene: A novel prognostic factor in patients with acute myeloid leukemia.
    Rivera JC; Nuñez D; Millar E; Ramirez K; Chandía M; Aguayo C
    Int J Lab Hematol; 2023 Dec; 45(6):833-838. PubMed ID: 37621152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.
    Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of CEBPA mutational subgroups in adult AML.
    Georgi JA; Stasik S; Kramer M; Meggendorfer M; Röllig C; Haferlach T; Valk P; Linch D; Herold T; Duployez N; Taube F; Middeke JM; Platzbecker U; Serve H; Baldus CD; Muller-Tidow C; Haferlach C; Koch S; Berdel WE; Woermann BJ; Krug U; Braess J; Hiddemann W; Spiekermann K; Boertjes EL; Hills RK; Burnett A; Ehninger G; Metzeler K; Rothenberg-Thurley M; Dufour A; Dombret H; Pautas C; Preudhomme C; Fenwarth L; Bornhäuser M; Gale R; Thiede C
    Leukemia; 2024 Feb; 38(2):281-290. PubMed ID: 38228680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
    Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
    Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.
    Tien FM; Hou HA
    Int J Hematol; 2024 Nov; 120(5):541-547. PubMed ID: 38671183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
    Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
    Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
    Mendoza H; Podoltsev NA; Siddon AJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
    Pabst T; Eyholzer M; Fos J; Mueller BU
    Br J Cancer; 2009 Apr; 100(8):1343-6. PubMed ID: 19277035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CEBPA and GATA2 mutation and a transient blood group discrepancy in a patient with acute myeloid leukaemia.
    Flores-Morán MS; Fuste E
    Transfus Med; 2024 Oct; 34(5):457-458. PubMed ID: 39183374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.